<DOC>
	<DOC>NCT00390520</DOC>
	<brief_summary>This mechanistic study is designed to investigate the effect of vildagliptin on the sensitivity of the a-cell to glucose under hypoglycemic conditions in patients with type 2 diabetes (T2DM).</brief_summary>
	<brief_title>Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Patients with T2DM, diagnosed at least 6 weeks prior to visit 1, who have had no treatment with oral antidiabetic agents for at least 12 weeks prior to study entry (visit 1) and no treatment with oral antidiabetic agents at any time in the past for &gt; 3 consecutive months &gt;/= 18 years Body mass index in the range of 2235 kg/m2 HbA1c &lt;/=7.5% Type 1 diabetes Acute metabolic diabetic complications Evidence of significant diabetic complications Insulin treatment within the past 6 months Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>glucagon</keyword>
	<keyword>hypoglycemia</keyword>
</DOC>